The protective effect of flagellin A and B as candidate vaccine against Pseudomonas aeruginosa respiratory infections

Mohammed Jaafar Al-Anssari; Alaa H. Al-Charrakh

doi:10.53730/ijhs.v6nS1.5497

Authors

Mohammed Jaafar Al-Anssari College of Medical and Health Technologies / University of AL-Kafeel, Al-Najaf, Iraq and Dept. of Microbiology/ College of Medicine / University of Babylon, Hilla, Iraq
Alaa H. Al-Charrakh
ahani67@gmail.com
Dept. of Microbiology/ College of Medicine / University of Babylon, Hilla, Iraq

Keywords:

Pseudomonas aeruginosa, Flagellin, Th17, vaccine, CD161

Abstract

Background: Multi drug resistance (MDR) P. aeruginosa consider the main cause of morbidity in hospitalize patients suffering from chronic airway infections such as chronic pulmonary disease, pneumonia and cystic fibrosis (CF). Also, the rapidly development of antibiotic resistance to the last generations of a broad spectrum antibiotic were detected for many P. aeruginosa isolates. Accordingly the vaccines have the potential to prevent and treatment such infections. Aim: The present study aimed to investigate the active immunization using flagellin to provide the protection against MDR P. aeruginosa clinical isolates in the fatal respiratory acute infection in animal model. Methods: Flagellin a and flagellin b purified partially from local isolates of P. aeruginosa were used for animal immunization. After that the animals were immunized intranasally after sedative the animal by applying 10 μl of flagellin a (4.8 μg), or flagellin b (4.8 μgl) on each nostril for 100 mg weight of rat at weekly intervals. After week from the 6^th dose, the animal were exposed to 2_*10⁷CFU of P. aeruginosa direct into each nostril (intranasally).

Downloads

Download data is not yet available.

References

Who Publishes List of Bacteria For Which New Antibiotics are Urgently Needed. Saudi Med J. 2017;

Adlbrecht C, Wurm R, Depuydt P, Spapen H, Lorente JA, Staudinger T, et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial. 2020;24(1):1–10.

Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa [version 1; peer review: 2 approved]. F1000Research. 2019;8:1–14.

Grimwood K, Kyd JM, Owen SJ, Massa HM, Cripps AW. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum vaccines & Immunother. 2015 Jan;11(1):14–20.

Hasan TH, Al-Harmoosh RA. Mechanisms of antibiotics resistance in bacteria. Syst Rev Pharm. 2020;11(6):817–23.

Huang W, Hamouche J El, Wang G, Smith M, Yin C, Dhand A, et al. Integrated genome-wide analysis of an isogenic pair of Pseudomonas aeruginosa clinical isolates with differential antimicrobial resistance to ceftolozane/tazobactam, ceftazidime/avibactam, and piperacillin/tazobactam. Int J Mol Sci. 2020;21(3):1026.

Centers for Disease Control Prevention and Others. Antibiotic resistance threats in the United States, 2019. US; 2020.

Bianconi I, Alcalá-Franco B, Scarselli M, Dalsass M, Buccato S, Colaprico A, et al. Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa. Front Immunol. 2019 Jan 9;9:3021.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar 1;18(3):318–27.

Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019 Aug 18;32(4):1–52.

Al-Khudhairy MK, Al-Shammari MMM. Prevalence of metallo-β-lactamase–producing Pseudomonas aeruginosa isolated from diabetic foot infections in Iraq. New Microbes New Infect. 2020;35:100661.

Lister PD, Wolter DJ, Hanson ND. Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin Microbiol Rev. 2009 Oct;22(4):582–610.

Moradali MF, Ghods S, Rehm BHA. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Front Cell Infect Microbiol . 2017 Feb 15;7(FEB):39.

Ramos HC, Rumbo M, Sirard JC. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol. 2004;12(11):509–17.

Al-Anssari M, Al-Charrakh A. Isolation and purification of type A and B flagellin from Pseudomonas aeruginosa for preclinical use. J App Pharm Sci, 2022 (In Press).

ULAM Veterinary Staff. Guidelines on Anesthesia and Analgesia in Rats. University of Michigan; 2021. Available from: https://az.research.umich.edu/animalcare/guidelines/guidelines-anesthesia-and-analgesia-rats

Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol. 2011;2(AUG):1–7.

Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, et al. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012;186(5):420–7.

Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, et al. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol. 2008;181(7):4965–75.

Shahrara S, Pickens SR, Mandelin AM, Karpus WJ, Huang Q, Kolls JK, et al. IL-17--mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol. 2010;184(8):4479–87.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–33.

Billerbeck E, Kang Y-H, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci. 2010;107(7):3006–11.

Kolls JK, Kanaly ST, Ramsay AJ. Interleukin-17: an emerging role in lung inflammation. Am J Respir Cell Mol Biol. 2003;28(1):9–11.

Chen K, McAleer JP, Lin Y, Paterson DL, Zheng M, Alcorn JF, et al. Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity. 2011;35(6):997–1009.

Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25(3):335–40.

Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–28.

Li Y, Gierahn T, Thompson CM, Trzciński K, Ford CB, Croucher N, et al. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog. 2012;8(11):e1002989.

Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, et al. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol. 2011 Mar;61(2):179–88.

Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171(11):1209–23.

Buret A, Dunkley ML, Pang G, Clancy RL, Cripps AW. Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha. Infect Immun. 1994;62(12):5335–43.